SynthesisJournal of global health2026
Oral amoxicillin for management of fast breathing or chest indrawing pneumonia without danger signs in children aged 2-59 months: a systematic review and meta-analysis.
Synthesis in Journal of global health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: World Health Organization (WHO) guidelines recommend oral amoxicillin as first-line therapy for pneumonia in children aged 2-59 months. However, uncertainty remains regarding its effectiveness compared with no antibiotics for fast breathing pneumonia and with injectable antibiotics for chest indrawing pneumonia without danger signs. Methods: We searched PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (January 2000-August 2024) for randomised and quasi-randomised trials without language restrictions. Eligible studies compared oral amoxicillin vs. no antibiotics for fast breathing pneumonia or outpatient oral amoxicillin vs. inpatient injectable antibiotics for chest indrawing pneumonia without danger signs in children (2-59 months). Pooled relative risks (RRs) with 95% confidence intervals (CIs) were estimated using a random-effects model; certainty was assessed using GRADE. Results: Four trials (n = 7,699) compared oral amoxicillin with no antibiotics for fast breathing pneumonia, and three (n = 4,864) compared oral with injectable antibiotics for chest indrawing pneumonia. For fast breathing pneumonia, oral amoxicillin reduced treatment failure by 16% at day 14 (RR = 0.84; 95% CI = 0.75, 0.94, I Conclusions: In children (2-59 months), oral amoxicillin significantly reduces treatment failure compared to no antibiotics for fast breathing pneumonia and is comparable to injectable antibiotics for chest indrawing pneumonia without danger signs. Notably, oral amoxicillin was associated with a 72% reduction in mortality compared with injectable antibiotics in children with chest-indrawing pneumonia, although absolute risk differences were small. These findings support its broader implementation as an accessible, programmatically feasible, and WHO-recommended option for pneumonia management in low-resource settings. Registration: PROSPERO: CRD42023439851.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.